Sjögren's Disease (SjD) is a chronic autoimmune disorder primarily causing dry eyes and mouth. Beyond these common symptoms, SjD carries a significant risk of B-cell non-Hodgkin lymphoma. This increased lymphoma risk is a primary concern, highlighting the urgent need for reliable biomarkers to identify at-risk individuals and guide treatment.
A recent prospective study, conducted within the French ASSESS cohort, offers important insights. The researchers focused on a Proliferation-Inducing Ligand (APRIL), a key cytokine that helps B cells survive and activate, particularly during their later stages of development. These B cells are central to SjD's autoimmune nature, driving excessive antibody production and immune complex formation, which contribute to both systemic complications and the development of lymphoma. While BAFF, another B-cell cytokine, has been linked to Sjögren's syndrome (SjD) and lymphoma, the specific role of APRIL was less understood. Their study aimed to clarify the precise involvement of APRIL.
Thanks for reading The Journal Club! Subscribe for free to receive new posts and support my work.
The Study: Methods and Key Findings
The researchers analyzed data from the French ASSESS cohort, a prospective study with a 17-year follow-up. They included 337 SjD patients (diagnosed by 2016 ACR/EULAR criteria) and 40 healthy donors.
They measured serum APRIL levels at enrollment using ELISA. Patients were categorized into clusters based on disease activity and lymphoma risk:
Cluster 1: B-cell activation markers present, no systemic issues.
Cluster 2: Moderate to severe disease activity with systemic complications.
Cluster 3: Low disease activity and lymphoma risk, but high symptom burden.
The team compared APRIL levels in patients who developed incident lymphoma (n = 9) or had prevalent lymphoma (n = 16) with those in other SjD groups and healthy donors. They used statistical models to assess associations between APRIL and known lymphoma predictors (like clinESSDAI, specific ESSDAI domains, and lab markers).
Key Findings:
APRIL levels increased with disease severity and lymphoma risk. Median APRIL levels rose from 0.36 ng/ml in healthy donors to 2.33 ng/ml in SjD-associated lymphoma patients.
Patients who developed incident lymphoma had the highest APRIL levels (2.8 ng/ml), significantly higher than all other groups.
APRIL remained significantly associated with lymphoma in multivariate analyses (OR 1.1; 95% CI [1-1.17]; p=0.045), even when considering other factors. For incident lymphoma, APRIL (OR 1.1; 95% CI [1.01-1.21]; p = 0.02) and CXCL13 were independently associated.
APRIL levels were also significantly associated with disease activity (clinESSDAI, ESSDAI domains) and numerous B-cell activation markers.
Why This Matters: Preventing Lymphoma in SjD
These findings have significant implications for managing SjD, particularly in terms of lymphoma prevention. Elevated serum APRIL is a promising, easily measurable biomarker for high lymphoma risk, enabling earlier identification and closer monitoring. APRIL's central role also suggests it could be a therapeutic target to control B-cell overactivity, reduce inflammation, and, critically, lower the risk of lymphoma. This research offers both a valuable prediction tool and a new avenue for therapies to prevent this severe complication and improve outcomes for people with Sjögren's Disease.
#SjogrensDisease
#Sjogren
Thanks for reading The Journal Club! Subscribe for free to receive new posts and support my work.